Envestnet Portfolio Solutions
REGN icon

Envestnet Portfolio Solutions’s Regeneron Pharmaceuticals REGN Stock Holding History

Envestnet Portfolio Solutions’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$592K Buy
950
+7
+0.7% +$4.76K ﹤0.01% 924
2026
Q1 		$728K Sell
943
-1,252
-57% -$959K ﹤0.01% 752
2025
Q4 		$1.69M Buy
2,195
+12
+0.5% +$8.15K 0.01% 585
2025
Q3 		$1.23M Buy
2,183
+14
+0.6% +$7.92K ﹤0.01% 674
2025
Q2 		$1.14M Buy
2,169
+398
+22% +$222K ﹤0.01% 747
2025
Q1 		$1.12M Sell
1,771
-913
-34% -$628K ﹤0.01% 756
2024
Q4 		$1.91M Buy
2,684
+713
+36% +$598K 0.01% 678
2024
Q3 		$2.07M Buy
1,971
+279
+16% +$310K 0.01% 649
2024
Q2 		$1.78M Buy
1,692
+104
+7% +$101K 0.01% 667
2024
Q1 		$1.53M Buy
1,588
+400
+34% +$380K 0.01% 716
2023
Q4 		$1.04M Buy
1,188
+370
+45% +$305K ﹤0.01% 785
2023
Q3 		$673K Buy
+818
New +$643K ﹤0.01% 865

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Envestnet Portfolio Solutions's REGN Position: Q2 2026 in Review

Envestnet Portfolio Solutions increased its Regeneron Pharmaceuticals (REGN) stake by 0.74% in Q2 2026, buying an estimated $4.76K and bringing the position to 950 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Envestnet Portfolio Solutions first reported a position in REGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.07M in Q3 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Envestnet Portfolio Solutions held 950 shares of Regeneron Pharmaceuticals worth $592K as of Q2 2026.
  • Envestnet Portfolio Solutions bought 7 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.76K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q2 2026, its #924 holding.
  • Envestnet Portfolio Solutions first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Envestnet Portfolio Solutions's Regeneron Pharmaceuticals position peaked at $2.07M in Q3 2024.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2026, filed 20 Jul 2026.